Ocular Therapeutix Enrolls First Patient In SOL-X Long-term Extension Trial For Axpaxli (Also Known As OTX-TKI) For Wet Age-related Macular Degeneration

Benzinga Newsdesk www.benzinga.com Positive 77.9%